NLA Meeting Highlights

NLA Meeting Highlights

From Vegas to New York, the NLA Highlights Programs are comprehensive reviews of the most popular presentations from our previous meetings. Below you will find a list a meeting highlights from past events. Please feel free to review the presentations.
  • NLA-EAS 2021 Joint Educational Session Series: Women, Atherosclerosis, and Lipids: What is Different?
  • Sponsored Expert Theater: How to efficiently get our patients to LDL-C goals - a call to action
 
  • Exploring the Systems of Care in ASCVD Management, a healthcare industry panel discussion from the NLA
 
  • First Human Trial of a Loading Dose of Icosapent Ethyl in Patients with COVID-19: Primary Results of the VASCEPA COVID-19 CardioLink-9 Randomized Trial, presented by Deepak L Bhatt, MD, MPH
  • Reductions in lipoprotein(a) with inclisiran– Analysis from ORION-10 and ORION-11, presented by Frederick Raal, FRCP, FCP(SA), Cert Endo, MMED, PhD
  • EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (Encore Presentation), presented by Michael Miller, MD, FACC, FAHA
2018 Scientific Sessions - Las Vegas, NV
  • CRISPR-Cas9 genome editing for treatment of atherogenic dyslipidemia
  • Update on Clinical Trials: How Will This Affect Practice in the Future?
  • Resistant Hypertension: A Practical Approach to the Guidelines
  • These activity highlights supported by Alexion Pharmaceuticals, Inc.
 
  • Bariatric Surgery: What a Lipidologist Needs to Know
  • Lipodystrophy
  • Cream of Tomato Soup" Blood: What's the Skinny on FCS and Other Chylomicronemic States?
  • Cholesterol Screening in Children and Young Adults. Where are we going?
 
  • Noninvasive Imaging for Atherosclerosis Regression
  • Identification of Rare Triglyceride Disorders
  • Therapeutic Options for Triglyceride Lowering
  • Is Lower Better for LDL or is there a “Sweet Spot”
 
2016 Scientific Sessions - New Orleans, LA
  • Uncommon Dyslipidemias with Common Presentations
  • Human Genetics and CV Risk Assessment
  • Lipoprotein(a) as a Cause of Cardioborbobbvascular Disease
  • Management of FH in Pregnancy: An art or an oxymoron?
  • Gut Microbiota and Atherothrombotic Heart Disease
  • Updates to the 2016 NLA Annual Summary - Secrets Revealed
  • PCSK9 Inhibitors: Practical Aspects of their use in Patients with Familial Hypercholesterolemia
  • Key Clinical Lipidology Publications: 2015-16
  • Should PCSK9 Inhibitors be Used in Statin Intolerant Patients?
  • PCSK9 Inhibitors: Impact on the Management of LDL Apheresis Candidates and LDL Apheresis Patients
 
  • Keeping NLA Members Up-to-Date: Key Articles for the 2016 NLA Annual Summary
  • NLA Recommendations for Patient-Centered Management of Dyslipidemia- Part 2
  • Statin Intolerance as a Barrier to Atherosclerotic Disease Risk Reduction
 
  • NLA Recommendations for Management of Special Populations
  • New Evidence & Outcomes: Information Lipidologists Need to Know
  • Hypertension: How New Guidelines Should Change Your Practice?
  • Case Discussions: Treatment Strategies for High Risk Populations
  • South Asian Ethnicity - Management and Associated Risk
2015 Spring CLU - Denver, CO
  • Two Different Prevention Approaches Two Different Perspectives
  • Inflammation, Risk Prediction, and the Prevention of ASCVD
  • Clinical Management of Hypertriglyceridemia: State of the Art 2015
  • ApoB in Risk Assessment and the Diagnosis and Treatment of the Atherogenic Dyslipoproteinemias
Publish Date: 
Thursday, July 7, 2016 - 10:45

This page was last updated: Jul 16, 2021